2. Academic Validation
  3. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans

Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans

  • Nat Med. 2009 Apr;15(4):380-3. doi: 10.1038/nm.1942.
Hiroshi Watanabe 1,  Nagesh Chopra,  Derek Laver,  Hyun Seok Hwang,  Sean S Davies,  Daniel E Roach,  Henry J Duff,  Dan M Roden,  Arthur A M Wilde,  Björn C Knollmann
Affiliations

Affiliation

  • 1 Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
PMID: 19330009 DOI: 10.1038/nm.1942
Abstract

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal inherited arrhythmia syndrome in which drug therapy is often ineffective. We discovered that flecainide prevents arrhythmias in a mouse model of CPVT by inhibiting cardiac ryanodine receptor-mediated CA(2+) release and thereby directly targeting the underlying molecular defect. Flecainide completely prevented CPVT in two human subjects who had remained highly symptomatic on conventional drug therapy, indicating that this currently available drug is a promising mechanism-based therapy for CPVT.

Figures
Products